Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
77.40
-0.19 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
August 31, 2022
Via
ACCESSWIRE
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
August 30, 2022
Via
ACCESSWIRE
Moderna to Host R&D Day on Thursday, September 8, 2022
August 29, 2022
Via
ACCESSWIRE
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
August 29, 2022
Via
ACCESSWIRE
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
August 26, 2022
Via
ACCESSWIRE
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
August 23, 2022
Via
ACCESSWIRE
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
August 22, 2022
Via
ACCESSWIRE
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 03, 2022
Via
ACCESSWIRE
James Mock Joins Moderna as Chief Financial Officer
August 17, 2022
Via
ACCESSWIRE
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
August 15, 2022
Via
ACCESSWIRE
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
August 08, 2022
Via
ACCESSWIRE
3 Health Care Stocks in Great Financial Health
August 02, 2022
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.
Via
MarketBeat
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
July 29, 2022
Via
ACCESSWIRE
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
July 29, 2022
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Is Moderna's Cheaper Valuation A Buying Signal?
July 28, 2022
Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 22, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 22, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years
July 19, 2022
Via
ACN Newswire
Exposures
COVID-19
Is it Time to Cash Out Novavax Stock?
July 19, 2022
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
July 18, 2022
Via
ACCESSWIRE
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
July 18, 2022
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
July 18, 2022
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
July 14, 2022
Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
July 13, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
July 12, 2022
Moderna advances global health commitment with mRNA vaccine candidate against the Nipah virus, a lethal pathogen with pandemic potential
From
Moderna, Inc.
Via
AccessWire
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
July 11, 2022
mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma
From
Moderna, Inc.
Via
AccessWire
Exposures
Product Safety
3 Growth Stocks Trading at Value P/E's
July 07, 2022
The depressed P/E ratios of these three S&P 500 growth stocks make them value stocks in a growth wrapper—and bargain buys for investors.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
June 22, 2022
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.